VarmX, an Ysios portfolio company, partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

by Ysios Capital

Under the terms of the strategic collaboration agreement, CSL will fully fund VarmX’s global Phase 3 EquilibriX-S trial evaluating VMX-C001 in patients taking FXa DOACs who require urgent surgery. C...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Regenera Levante partners with Magnum Ca...

by Magnum Capital Partners

Over little more than a decade, Regenera has built a strong track reco...

Photos Stream